Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ZBIO
ZBIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ZBIO News
Purcell & Lefkowitz Investigates Zenas BioPharma for Potential Fiduciary Breaches
Feb 17 2026
PRnewswire
Zenas BioPharma Under Investigation for Securities Fraud
Feb 13 2026
PRnewswire
Obexelimab Achieves Significant Results in Multiple Sclerosis Trial
Feb 09 2026
Newsfilter
Zenas BioPharma CEO Buys $1M in Stock, Shares Rise 11%
Feb 04 2026
seekingalpha
Pomerantz Investigates Zenas BioPharma After 51.86% Stock Drop
Jan 22 2026
PRnewswire
Zenas BioPharma Under Investigation as Stock Plummets 51.86%
Jan 20 2026
Globenewswire
Zenas BioPharma Grants 100,000 Stock Options to New Employee at $19.93 Exercise Price
Jan 16 2026
Globenewswire
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
Jan 12 2026
Benzinga
NIO Inc Reaches 1 Million Vehicle Production Milestone with 71.7% Q4 Delivery Growth
Jan 10 2026
Benzinga
U.S. Stocks Rise on Venezuela Action; Chevron Shares Up 5.8%
Jan 10 2026
Benzinga
Zenas BioPharma Shares Plunge 51.86% Following Disappointing Phase 3 Trial Results
Jan 09 2026
PRnewswire
Zenas BioPharma Shares Plunge 51.86% Following Phase 3 Trial Results
Jan 06 2026
Globenewswire
Zenas BioPharma Shares Plunge Over 50% Following Phase 3 Trial Results Shortfall
Jan 06 2026
Benzinga
Cyclerion Therapeutics Expands Collaboration with Medsteer, Shares Surge 44.2%
Jan 06 2026
Benzinga
Zenas BioPharma (ZBIO) Shares Plunge 57.3% Despite Positive INDIGO Trial Results
Jan 05 2026
NASDAQ.COM
ZBIO Options Volume Hits 1,848 Contracts, Exceeding 52% of Daily Average
Jan 05 2026
NASDAQ.COM
Show More News
